Why the study?
Does deep hypothermic circulatory arrest reduce perioperative mortality in patients undergoing resection for renal cell carcinoma with level IV tumour thrombus using cardiopulmonary bypass?
Does deep hypothermic circulatory arrest reduce perioperative mortality in patients undergoing resection for renal cell carcinoma with level IV tumour thrombus using cardiopulmonary bypass?
In patients undergoing resection for RCC with level IV tumour thrombus using cardiopulmonary bypass, the addition of deep hypothermic circulatory arrest may significantly reduce perioperative mortality.
Answers are grounded in this paper and cite their sources.
DHCA may warrant consideration in RCC level IV thrombus resection with bypass; leaves open randomized confirmation of mortality benefit.
OBJECTIVE: • To review experience with nephrectomy/thrombectomy for a renal cell carcimoma (RCC) with a level IV tumour thrombus and to evaluate the benefit of deep hypothermic circulatory arrest (DHCA) with cardiopulmonary bypass (CPBP). PATIENTS AND METHODS: • A multi-institutional retrospective database was created to assess the outcomes of surgery for RCC and associated level IV tumour thrombus from 1983 to 2007. Patients were identified based on radiographic records/operative findings. • Only cases using CPBP were analysed. Clinicopathological and operative characteristics including use of DHCA were recorded. • Overall survival (OS) for all patients and by use of DHCA was assessed. Comparisons of clinical and operative characteristics by use of DHCA were performed. • A Cox regression model determined predictors of perioperative/in-hospital mortality. RESULTS: • In all, 63 patients underwent resection with CPBP; overall perioperative mortality was 22.2%. • There were no significant differences in clinicopathological characteristics, operative duration, estimated blood loss, transfusions, and hospital stay by use of DHCA. • Perioperative mortality rate was lower in patients undergoing DHCA (8.3% vs 37.5%, P = 0.006). • The median OS was longer for the patients undergoing DHCA (15.8 vs 7.7 months); however, this failed to reach statistical significance (P = 0.357). • On multivariate analysis, age of > 60 years (hazard ratio [HR] 6.7, 95% confidence interval [CI] 1.5-31.1, P = 0.015) and the use of DHCA (HR 0.13, 95% CI 0.036-0.51, P = 0.003) were independent predictors of perioperative mortality. CONCLUSIONS: • Radical nephrectomy and level IV tumour thrombectomy is associated with significant mortality. • The use of DHCA does not appear to adversely affect operative characteristics and may limit perioperative mortality. • Further prospective studies should be performed to confirm the benefit of DHCA.
No takes yet. Share an insight, caveat, or question.
Shuch et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: